Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Using BM and PET/CT to assess MRD status in myeloma & lymphoma patients post-CAR-T therapy

Radhika Bansal • 11 Dec 2022
ASH 2022
Multiple Myeloma CAR-T

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discusses using a combination of bone marrow (BM) and PET/CT to assess measurable residual disease (MRD) status after CAR-T therapy for patients with multiple myeloma (MM). In this study, patients that were MRD negative for both BM and PET had the longest PFS at one month. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Radhika Bansal

2:22
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
Radhika Bansal • 9 Dec 2023
1:49
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal • 9 Dec 2023
2:00
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal • 11 Dec 2022
2:23
Prophylactic dexamethasone use with CAR-T therapy: real-world practice and outcomes
Radhika Bansal • 11 Dec 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals